Cargando…
Antidepressants- and antipsychotics-induced hepatotoxicity
Drug-induced liver injury (DILI) is a serious health burden. It has diverse clinical presentations that can escalate to acute liver failure. The worldwide increase in the use of psychotropic drugs, their long-term use on a daily basis, common comorbidities of psychiatric and metabolic disorders, and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781826/ https://www.ncbi.nlm.nih.gov/pubmed/33398419 http://dx.doi.org/10.1007/s00204-020-02963-4 |
_version_ | 1783631757768130560 |
---|---|
author | Todorović Vukotić, Nevena Đorđević, Jelena Pejić, Snežana Đorđević, Neda Pajović, Snežana B. |
author_facet | Todorović Vukotić, Nevena Đorđević, Jelena Pejić, Snežana Đorđević, Neda Pajović, Snežana B. |
author_sort | Todorović Vukotić, Nevena |
collection | PubMed |
description | Drug-induced liver injury (DILI) is a serious health burden. It has diverse clinical presentations that can escalate to acute liver failure. The worldwide increase in the use of psychotropic drugs, their long-term use on a daily basis, common comorbidities of psychiatric and metabolic disorders, and polypharmacy in psychiatric patients increase the incidence of psychotropics-induced DILI. During the last 2 decades, hepatotoxicity of various antidepressants (ADs) and antipsychotics (APs) received much attention. Comprehensive review and discussion of accumulated literature data concerning this issue are performed in this study, as hepatotoxic effects of most commonly prescribed ADs and APs are classified, described, and discussed. The review focuses on ADs and APs characterized by the risk of causing liver damage and highlights the ones found to cause life-threatening or severe DILI cases. In parallel, an overview of hepatic oxidative stress, inflammation, and steatosis underlying DILI is provided, followed by extensive review and discussion of the pathophysiology of AD- and AP-induced DILI revealed in case reports, and animal and in vitro studies. The consequences of some ADs and APs ability to affect drug-metabolizing enzymes and therefore provoke drug–drug interactions are also addressed. Continuous collecting of data on drugs, mechanisms, and risk factors for DILI, as well as critical data reviewing, is crucial for easier DILI diagnosis and more efficient risk assessment of AD- and AP-induced DILI. Higher awareness of ADs and APs hepatotoxicity is the prerequisite for their safe use and optimal dosing. |
format | Online Article Text |
id | pubmed-7781826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-77818262021-01-05 Antidepressants- and antipsychotics-induced hepatotoxicity Todorović Vukotić, Nevena Đorđević, Jelena Pejić, Snežana Đorđević, Neda Pajović, Snežana B. Arch Toxicol Review Article Drug-induced liver injury (DILI) is a serious health burden. It has diverse clinical presentations that can escalate to acute liver failure. The worldwide increase in the use of psychotropic drugs, their long-term use on a daily basis, common comorbidities of psychiatric and metabolic disorders, and polypharmacy in psychiatric patients increase the incidence of psychotropics-induced DILI. During the last 2 decades, hepatotoxicity of various antidepressants (ADs) and antipsychotics (APs) received much attention. Comprehensive review and discussion of accumulated literature data concerning this issue are performed in this study, as hepatotoxic effects of most commonly prescribed ADs and APs are classified, described, and discussed. The review focuses on ADs and APs characterized by the risk of causing liver damage and highlights the ones found to cause life-threatening or severe DILI cases. In parallel, an overview of hepatic oxidative stress, inflammation, and steatosis underlying DILI is provided, followed by extensive review and discussion of the pathophysiology of AD- and AP-induced DILI revealed in case reports, and animal and in vitro studies. The consequences of some ADs and APs ability to affect drug-metabolizing enzymes and therefore provoke drug–drug interactions are also addressed. Continuous collecting of data on drugs, mechanisms, and risk factors for DILI, as well as critical data reviewing, is crucial for easier DILI diagnosis and more efficient risk assessment of AD- and AP-induced DILI. Higher awareness of ADs and APs hepatotoxicity is the prerequisite for their safe use and optimal dosing. Springer Berlin Heidelberg 2021-01-05 2021 /pmc/articles/PMC7781826/ /pubmed/33398419 http://dx.doi.org/10.1007/s00204-020-02963-4 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Todorović Vukotić, Nevena Đorđević, Jelena Pejić, Snežana Đorđević, Neda Pajović, Snežana B. Antidepressants- and antipsychotics-induced hepatotoxicity |
title | Antidepressants- and antipsychotics-induced hepatotoxicity |
title_full | Antidepressants- and antipsychotics-induced hepatotoxicity |
title_fullStr | Antidepressants- and antipsychotics-induced hepatotoxicity |
title_full_unstemmed | Antidepressants- and antipsychotics-induced hepatotoxicity |
title_short | Antidepressants- and antipsychotics-induced hepatotoxicity |
title_sort | antidepressants- and antipsychotics-induced hepatotoxicity |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781826/ https://www.ncbi.nlm.nih.gov/pubmed/33398419 http://dx.doi.org/10.1007/s00204-020-02963-4 |
work_keys_str_mv | AT todorovicvukoticnevena antidepressantsandantipsychoticsinducedhepatotoxicity AT đorđevicjelena antidepressantsandantipsychoticsinducedhepatotoxicity AT pejicsnezana antidepressantsandantipsychoticsinducedhepatotoxicity AT đorđevicneda antidepressantsandantipsychoticsinducedhepatotoxicity AT pajovicsnezanab antidepressantsandantipsychoticsinducedhepatotoxicity |